
At the 2026 AANEM Annual Meeting, Michael Hehir, MD, makes the case that traditional immunotherapy still belongs at the center of long-term myasthenia gravis management, citing outcome data, patient burden, and the costs that often go undiscussed.

At the 2026 AANEM Annual Meeting, Michael Hehir, MD, makes the case that traditional immunotherapy still belongs at the center of long-term myasthenia gravis management, citing outcome data, patient burden, and the costs that often go undiscussed.

Mitzi Joi Williams, MD, and

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association (MDA), discussed the sessions he is most excited about at the 2027 MDA Clinical and Scientific Conference.

The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.

A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.

Cemdisiran (Livsayis), Regeneron’s complement C5-directed siRNA dosed four times a year, can now treat adults in the US who have AChR-antibody-positive generalized myasthenia gravis.

FDA 510(k) clearance adds an 8F neurovascular access sheath to Perfuze’s portfolio, designed to accommodate aspiration catheters up to 0.088 inches, including Millipede88.

A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.

A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.

Results from Eli Lilly's phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.

At an HCPLive and NeurologyLive Clinical Forum in Orlando, David Z. Rose, MD, of USF Morsani College of Medicine, discussed residual recurrence risk, dual antiplatelet therapy duration, and factor XIa inhibition in noncardioembolic stroke.

The senior director of research at the Muscular Dystrophy Association discussed what the newly approved once-weekly C5 inhibitor adds to generalized myasthenia gravis care.

Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.

The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.

Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.

In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.

A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

NeurologyLive's Louie Pasculli previews key clinical trial readouts, long-term treatment data, and emerging therapeutic approaches in Alzheimer disease ahead of CTAD 2026, held November 16-19 in Boston, Massachusetts. [WATCH TIME: 4 MINUTES]

A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.